# Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL)

> **NCT01324180** · PHASE1 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 14 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Metformin
- **DRUG:** Vincristine
- **DRUG:** Dexamethasone
- **DRUG:** PEG-asparaginase
- **DRUG:** Doxorubicin
- **DRUG:** Intrathecal chemotherapy

## Key facts

- **NCT ID:** NCT01324180
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07-18
- **Primary completion:** 2016-11-16
- **Final completion:** 2017-07-27
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2017-08-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01324180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01324180, "Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01324180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*